Published in Antivir Ther on January 01, 2010
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). BMC Public Health (2011) 0.95
Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings. BMC Pregnancy Childbirth (2012) 0.92
Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. AIDS (2011) 0.82
Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral Treatment. AIDS Res Hum Retroviruses (2015) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med (2000) 23.10
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis (2006) 7.42
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet (2005) 6.60
Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 5.17
Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med (1999) 5.05
Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS (2008) 4.48
Reduced lopinavir exposure during pregnancy. AIDS (2006) 3.98
Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis (2004) 3.95
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Mixed effects models with censored data with application to HIV RNA levels. Biometrics (1999) 2.74
Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr (2008) 2.38
Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed (2004) 2.23
Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis (2007) 1.88
Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet (2004) 1.86
Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care (2008) 1.73
Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf (2007) 1.52
The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS (2006) 1.39
British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med (2008) 1.33
Young, seropositive, and pregnant: epidemiologic and psychosocial perspectives on pregnant adolescents with human immunodeficiency virus infection. Am J Obstet Gynecol (2007) 1.21
Contraceptive use among U.S. women with HIV. J Womens Health (Larchmt) (2007) 1.20
National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients. HIV Med (2007) 1.16
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol (2006) 1.15
Reproductive experience of HIV-infected women living in Europe. Hum Reprod (2008) 1.12
HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women. Int J STD AIDS (2007) 1.08
Increasing likelihood of further live births in HIV-infected women in recent years. BJOG (2005) 1.05
Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol (2008) 1.04
Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV. Cell Mol Biol (Noisy-le-grand) (2003) 1.01
Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr (2006) 1.00
Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women? AIDS (2008) 0.95
Fertility choices and management for HIV-positive women. Curr Opin HIV AIDS (2008) 0.86
Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1? Clin Infect Dis (2009) 0.86
Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child. Pediatr Infect Dis J (2006) 0.82
Levels and patterns of HIV RNA viral load in untreated pregnant women. Int J Infect Dis (2008) 0.81
Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther (2006) 0.80
Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues. Med Wieku Rozwoj (2004) 0.77